title: [Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].
abstract: Recent studies have shown efficacy to slow the decrease of forced vital capacity in patients with idiopathic pulmonary fibrosis. This summary refers to recent anti-fibrotic medications and describes current studies, indication for treatment and side effects, as well as discusses open questions of treatment.
authors.affiliation: 1 Universitätsklinik für Pneumologie, Inselspital, Bern.
authors.forename: Manuela
authors.initials: M
authors.lastname: Funke-Chambour
authors.affiliation: 1 Universitätsklinik für Pneumologie, Inselspital, Bern.
authors.forename: Thomas
authors.initials: T
authors.lastname: Geiser
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis* / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D011728:Pyridones / Q000008:administration & dosage* / Q000009:adverse effects; D019141:Respiratory System Agents / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005343:Fibrinolytic Agents; D007211:Indoles; D011728:Pyridones; D019141:Respiratory System Agents; C093844:pirfenidone; C530716:nintedanib